



# SINGAPORE

## Recent and planned developments in pharmaceutical policies 2025

### Current state of HTA and recent advances

- The Agency for Care Effectiveness (ACE) is Singapore's national HTA and clinical guidance agency. ACE's mandate includes conducting HTAs to support national funding decisions for medicines and medical devices.
- For medicines, HTA evaluations are either **company-led** or conducted **in-house** by ACE:
  - Cancer topics** are typically evaluated via **company-led submissions (CLS)**, while **non-cancer topics** are **assessed in-house**.
  - From 2024, ACE launched a **CLS pilot for selected non-cancer drugs and cell, tissue, and gene therapy products (CTGTPs)** after early signs that CLS reduces the time from regulatory approval to reimbursement (median: 281 vs 915 days).
- ACE has **regular professional engagements with other international HTA bodies**, including Australia's Pharmaceutical Benefits Advisory Committee, Canada's Drug Agency, and UK NICE to exchange best practices and discuss complex HTA challenges.



### Updates to Value-based pricing (VBP) approaches

- ACE negotiates prices and risk-sharing agreements (RSAs) in parallel with the HTA evaluations to inform funding decisions.
- Where feasible, internal and external price referencing, are conducted to assess fair prices for funding.
- More recently, RSAs have been extended to non-cancer drugs and vaccines.

RSA Breakdown		
Category	No. of treatments	Proportion (%)
Cancer drugs	40	62%
Non-cancer drugs	21	33%
CTGTPs	2	3%
Vaccines	1	2%

### Updates to reimbursement landscape

